D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD)

D. Boral Capital restated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has a $9.00 target price on the stock.

IVVD has been the topic of a number of other research reports. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. HC Wainwright cut their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, Morgan Stanley decreased their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $7.89.

Invivyd Stock Down 2.1 %

Shares of IVVD opened at $0.45 on Friday. Invivyd has a twelve month low of $0.40 and a twelve month high of $5.20. The firm has a 50 day moving average of $0.64 and a 200 day moving average of $0.90. The company has a market capitalization of $54.07 million, a P/E ratio of -0.23 and a beta of 0.64.

Insider Activity

In related news, Director Terrance Mcguire sold 150,000 shares of Invivyd stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00. Following the completion of the transaction, the director now directly owns 4,538,079 shares of the company’s stock, valued at approximately $2,768,228.19. The trade was a 3.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. State Street Corp raised its stake in shares of Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares in the last quarter. Marshall Wace LLP grew its position in shares of Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after buying an additional 31,992 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Invivyd by 232.0% during the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares in the last quarter. Duquesne Family Office LLC acquired a new position in Invivyd during the 2nd quarter valued at about $629,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Invivyd in the 2nd quarter valued at approximately $421,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.